Raymond James & Associates increased its stake in shares of Archrock, Inc. (NYSE:AROC – Free Report) by 15.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 158,108 shares of the energy company’s stock after purchasing an additional 20,896 shares during the quarter. Raymond James & Associates owned approximately 0.10% of Archrock worth $3,200,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AROC. Allspring Global Investments Holdings LLC bought a new position in Archrock during the first quarter worth $43,000. BNP Paribas Financial Markets raised its holdings in Archrock by 77.2% during the 1st quarter. BNP Paribas Financial Markets now owns 69,992 shares of the energy company’s stock worth $1,377,000 after purchasing an additional 30,493 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in Archrock by 9.0% during the 1st quarter. Janney Montgomery Scott LLC now owns 13,065 shares of the energy company’s stock worth $257,000 after purchasing an additional 1,079 shares during the last quarter. Texas Permanent School Fund Corp increased its stake in shares of Archrock by 1.4% in the 1st quarter. Texas Permanent School Fund Corp now owns 120,191 shares of the energy company’s stock valued at $2,364,000 after acquiring an additional 1,607 shares during the last quarter. Finally, Duality Advisers LP bought a new stake in shares of Archrock in the 1st quarter valued at about $372,000. Institutional investors own 95.45% of the company’s stock.
Archrock Stock Performance
NYSE:AROC opened at $20.19 on Tuesday. The stock’s 50-day simple moving average is $20.33 and its 200 day simple moving average is $20.15. Archrock, Inc. has a twelve month low of $13.15 and a twelve month high of $23.44. The firm has a market capitalization of $3.41 billion, a PE ratio of 22.69 and a beta of 1.52. The company has a quick ratio of 0.94, a current ratio of 1.53 and a debt-to-equity ratio of 1.80.
Archrock Increases Dividend
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. began coverage on Archrock in a research report on Friday, September 6th. They issued an “overweight” rating and a $24.00 price objective for the company. Mizuho assumed coverage on Archrock in a research note on Wednesday, October 2nd. They issued an “outperform” rating and a $24.00 price target on the stock. Royal Bank of Canada increased their price target on Archrock from $22.00 to $26.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Stifel Nicolaus increased their price objective on Archrock from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Finally, Citigroup initiated coverage on Archrock in a research report on Friday, September 27th. They set a “buy” rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.50.
Read Our Latest Analysis on Archrock
About Archrock
Archrock, Inc, together with its subsidiaries, operates as an energy infrastructure company in the United States. The company operates in two segments, Contract Operations and Aftermarket Services. It engages in the designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining of its owned fleet of natural gas compression equipment to provide natural gas compression services.
Further Reading
- Five stocks we like better than Archrock
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Intel: Is Now the Time to Be Brave?
- Insider Buying Explained: What Investors Need to Know
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Dividend King?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Want to see what other hedge funds are holding AROC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Archrock, Inc. (NYSE:AROC – Free Report).
Receive News & Ratings for Archrock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Archrock and related companies with MarketBeat.com's FREE daily email newsletter.